Tokyo Tape
Sign in
← H.U. Group Holdings

Half-year report · HY

4544.TEDINET S100X1GC
Period2025-04-01 → 2025-09-30
Filed2025-11-13
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥124.4bn2025-04-01 → 2025-09-30Cons.Net sales
Revenue¥243.0bn2024-04-01 → 2025-03-31Cons.Net sales (5-year summary)
Revenue¥120.0bn2024-04-01 → 2024-09-30Cons.Net sales
Operating income¥2.3bn2025-04-01 → 2025-09-30Cons.Operating income
Operating income¥956m2024-04-01 → 2024-09-30Cons.Operating income
Ordinary income¥305m2025-04-01 → 2025-09-30Cons.Ordinary income
Ordinary income¥4.7bn2024-04-01 → 2025-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income−¥1.3bn2024-04-01 → 2024-09-30Cons.Ordinary income
Profit before tax−¥187m2025-04-01 → 2025-09-30Cons.Income before income taxes
Profit before tax−¥1.6bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Net income (owners)¥205m2025-04-01 → 2025-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)¥2.8bn2024-04-01 → 2025-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥821m2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income¥142m2025-04-01 → 2025-09-30Cons.Profit loss
Net income−¥821m2024-04-01 → 2024-09-30Cons.Profit loss
Total assets¥274.0bnat 2025-09-30Cons.Assets
Total assets¥279.6bnat 2025-03-31Cons.Assets
Total assets¥291.4bnat 2024-09-30Cons.Total assets (5-year summary)
Total liabilities¥138.9bnat 2025-09-30Cons.Liabilities
Total liabilities¥142.3bnat 2025-03-31Cons.Liabilities
Net assets / equity¥135.1bnat 2025-09-30Cons.Net assets
Net assets / equity¥137.3bnat 2025-03-31Cons.Net assets
Net assets / equity¥136.1bnat 2024-09-30Cons.Net assets (5-year summary)
Cash and deposits¥39.6bnat 2025-09-30Cons.Cash and deposits
Cash and deposits¥40.9bnat 2025-03-31Cons.Cash and deposits
Cash & equivalents¥39.6bnat 2025-09-30Cons.Cash and cash equivalents
Cash & equivalents¥40.9bnat 2025-03-31Cons.Cash and cash equivalents
Cash & equivalents¥47.0bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥39.9bnat 2024-03-31vCons.Cash and cash equivalents
Operating cash flow¥6.2bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥22.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥6.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥2.0bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥16.0bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥9.8bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥5.8bn2025-04-01 → 2025-09-30Cons.Net cash provided by used in financing activities
Financing cash flow−¥5.3bn2024-04-01 → 2025-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥10.7bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥3.612025-04-01 → 2025-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥48.62024-04-01 → 2025-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-14.472024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥3.612025-04-01 → 2025-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio49.2%at 2025-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio49.0%at 2025-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio46.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 38
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2025-04-01 → 2025-09-30−¥2.3bn
Reconciling Itemsreconcilingrevenue intersegment2025-04-01 → 2025-09-30−¥2.3bn
Reconciling Itemsreconcilingsegment profit2025-04-01 → 2025-09-30−¥2.7bn
Clinical Lab Testing Businessreportable segmentrevenue2025-04-01 → 2025-09-30¥79.4bn
Clinical Lab Testing Businessreportable segmentrevenue external2025-04-01 → 2025-09-30¥79.2bn
Clinical Lab Testing Businessreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥249m
Clinical Lab Testing Businessreportable segmentsegment profit2025-04-01 → 2025-09-30−¥930m
In Vitro Diagnostics Businessreportable segmentrevenue2025-04-01 → 2025-09-30¥31.4bn
In Vitro Diagnostics Businessreportable segmentrevenue external2025-04-01 → 2025-09-30¥29.4bn
In Vitro Diagnostics Businessreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥2.0bn
In Vitro Diagnostics Businessreportable segmentsegment profit2025-04-01 → 2025-09-30¥4.8bn
Sterilization And Related Servicesreportable segmentrevenue2025-04-01 → 2025-09-30¥15.9bn
Sterilization And Related Servicesreportable segmentrevenue external2025-04-01 → 2025-09-30¥15.8bn
Sterilization And Related Servicesreportable segmentrevenue intersegment2025-04-01 → 2025-09-30¥90m
Sterilization And Related Servicesreportable segmentsegment profit2025-04-01 → 2025-09-30¥1.2bn
—segment totalrevenue2025-04-01 → 2025-09-30¥126.7bn
—segment totalrevenue external2025-04-01 → 2025-09-30¥124.4bn
—segment totalrevenue intersegment2025-04-01 → 2025-09-30¥2.3bn
—segment totalsegment profit2025-04-01 → 2025-09-30¥5.1bn
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥2.4bn
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥2.5bn
Clinical Lab Testing Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥76.7bn
Clinical Lab Testing Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥76.5bn
Clinical Lab Testing Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥205m
Clinical Lab Testing Businessreportable segmentsegment profit2024-04-01 → 2024-09-30−¥2.9bn
In Vitro Diagnostics Businessreportable segmentrevenue2024-04-01 → 2024-09-30¥31.2bn
In Vitro Diagnostics Businessreportable segmentrevenue external2024-04-01 → 2024-09-30¥29.0bn
In Vitro Diagnostics Businessreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥2.2bn
In Vitro Diagnostics Businessreportable segmentsegment profit2024-04-01 → 2024-09-30¥5.5bn
Sterilization And Related Servicesreportable segmentrevenue2024-04-01 → 2024-09-30¥14.5bn
Sterilization And Related Servicesreportable segmentrevenue external2024-04-01 → 2024-09-30¥14.4bn
Sterilization And Related Servicesreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥9m
Sterilization And Related Servicesreportable segmentsegment profit2024-04-01 → 2024-09-30¥879m
—segment totalrevenue2024-04-01 → 2024-09-30¥122.4bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥120.0bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥2.4bn
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.5bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 524
ItemContextValueUnit
Income before income taxesPrior1InterimDuration-1571000000JPY
Income before income taxesInterimDuration-187000000JPY
Income taxes currentPrior1InterimDuration2095000000JPY
Income taxes currentInterimDuration678000000JPY
Income taxes deferredPrior1InterimDuration-2845000000JPY
Income taxes deferredInterimDuration-1007000000JPY
Income taxesPrior1InterimDuration-749000000JPY
Income taxesInterimDuration-329000000JPY
Profit lossPrior1InterimDuration-821000000JPY
Profit lossInterimDuration142000000JPY
Profit loss attributable to non controlling interestsPrior1InterimDuration－JPY
Profit loss attributable to non controlling interestsInterimDuration-63000000JPY
Profit loss attributable to owners of parentPrior1InterimDuration-821000000JPY
Profit loss attributable to owners of parentInterimDuration205000000JPY
Profit lossPrior1InterimDuration-821000000JPY
Profit lossInterimDuration142000000JPY
Valuation difference on available for sale securities net of tax ociPrior1InterimDuration256000000JPY
Valuation difference on available for sale securities net of tax ociInterimDuration-42000000JPY
Foreign currency translation adjustment net of tax ociPrior1InterimDuration-2403000000JPY
Foreign currency translation adjustment net of tax ociInterimDuration1195000000JPY
Remeasurements of defined benefit plans net of tax ociPrior1InterimDuration142000000JPY
Remeasurements of defined benefit plans net of tax ociInterimDuration133000000JPY
Other comprehensive incomePrior1InterimDuration-2004000000JPY
Other comprehensive incomeInterimDuration1286000000JPY
Comprehensive incomePrior1InterimDuration-2826000000JPY
Comprehensive incomeInterimDuration1428000000JPY
Comprehensive income attributable to owners of the parentPrior1InterimDuration-2826000000JPY
Comprehensive income attributable to owners of the parentInterimDuration1491000000JPY
Comprehensive income attributable to non controlling interestsPrior1InterimDuration－JPY
Comprehensive income attributable to non controlling interestsInterimDuration-63000000JPY
Income before income taxesPrior1InterimDuration-1571000000JPY
Income before income taxesInterimDuration-187000000JPY
Depreciation and amortization ope cfPrior1InterimDuration9942000000JPY
Depreciation and amortization ope cfInterimDuration10765000000JPY
Amortization of goodwill ope cfPrior1InterimDuration230000000JPY
Amortization of goodwill ope cfInterimDuration329000000JPY
Equity in earnings losses of affiliates ope cfPrior1InterimDuration617000000JPY
Equity in earnings losses of affiliates ope cfInterimDuration1082000000JPY
Decrease increase in accounts receivable trade and contract assets ope cfPrior1InterimDuration1032000000JPY
Decrease increase in accounts receivable trade and contract assets ope cfInterimDuration-1125000000JPY
Decrease increase in inventories ope cfPrior1InterimDuration-257000000JPY
Decrease increase in inventories ope cfInterimDuration-1360000000JPY
Increase decrease in notes and accounts payable trade ope cfPrior1InterimDuration-1789000000JPY
Increase decrease in notes and accounts payable trade ope cfInterimDuration-39000000JPY
Increase decrease in provision for bonuses ope cfPrior1InterimDuration-1061000000JPY
Increase decrease in provision for bonuses ope cfInterimDuration-881000000JPY
Loss on liquidation of subsidiaries and affiliates ope cfPrior1InterimDuration817000000JPY
Loss on liquidation of subsidiaries and affiliates ope cfInterimDuration－JPY
Reversal of provision for compensation loss ope cfPrior1InterimDuration-678000000JPY
Reversal of provision for compensation loss ope cfInterimDuration－JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2025-03-31pass
balance sheet identityconsolidated 2025-09-30pass rounding
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2025-03-31pass
statement vs summary · net assetsconsolidated 2025-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2025-04-01/2025-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2025-04-01/2025-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2025-04-01/2025-09-30pass
statement vs summary · total assetsconsolidated 2025-03-31pass
statement vs summary · total assetsconsolidated 2025-09-30pass